Notice of Pre-AIA or AIA Status
The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA .
Detailed Action
This office action is in response to applicant’s communication filed on 8/21/26.
Claims 1, 3, 15-28 and 30-34 are pending in this application. Claims 3, 15-16, 19-20, 23-25, 28, 30, 32-34 remain withdrawn.
Due to applicant’s claim amendments filed 8/21/26, the claim objection and the 103 rejection over Jozefiak et al. are withdrawn. However, based on a new search in response to applicant’s amended claims, new rejections are in order.
Applicant’s elected species is the following compound:
PNG
media_image1.png
278
386
media_image1.png
Greyscale
Applicant’s elected species remains allowable.
Thus the new species to be examined is the following:
PNG
media_image2.png
380
572
media_image2.png
Greyscale
N-tosyl-L-phenylalanine, i.e., (S)-2-((4-methylphenyl)sulfonamido)-3-phenylpropanoic acid
Claims 1, 15-17 and 31 read on the new species.
Thus, additionally, claims 18, 21-22 and 26-27 are hereby withdrawn from consideration being non-readable on the new species. The search has not been extended to determine the patentability of the other species encompassed by the claims.
As a result, claims 1, 15-17 and 31 are being examined in this Office Action. Claims 1, 3, 15-28 and 30-34 are pending in this application. Claims 3, 18-28, 30 and 32-34 are withdrawn.
With regard to applicant’s request for rejoinder of claims withdrawn for being non-readable on the new species, since the new species reads on claims 1, 15-17 and 31, claims 3, 18-28 and 30 that do not read on the new species can be withdrawn since the search is not extended to determine the patentability of the other species encompassed by the claims.
Claim Rejections – 35 USC 112
The following is a quotation of 35 U.S.C. 112(b):
(b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention.
Claims 1, 15-17 and 31 are rejected under 35 U.S.C. 112(b) as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor regards as the invention.
Claim 1 recites proviso (c): “the phenyl in Z is substituted with at least one trifluoromethoxy substituent, the C6-C10 aryl in R2 is substituted with at least one substituent, and R3 is optionally substituted C1-C6 aminoalkyl”. However, amended claim 1 defines R3 as H or C1-C3 alkyl. Also, R3 is only found in the second R1 group, which has no R2.
Thus proviso (c) can never be met. It is not clear if R3 can be an aminoalkyl. It is also not clear which compounds proviso (c) is meant to cover.
Claims 15-17 and 31 are rejected as being dependent on claim 1.
Claim Rejections – 35 USC 102
In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status.
The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:
A person shall be entitled to a patent unless –
(a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention.
Claims 1 and 15-17 are rejected under 35 U.S.C. 102(a)(1) as being anticipated by Pyne et al. (“Cytochalasin Support Studies. 2. Chiral and Stereochemical Control via an Intramolecular Diels-Alder Reaction of a (Z)-Diene,” J. Am. Chem. Soc., 1980, 102(18), pages 5960-5962, pub date 1980).
The instant claims are drawn to the following compound of formula (I):
PNG
media_image3.png
143
289
media_image3.png
Greyscale
where R1 can be the following group:
PNG
media_image4.png
270
255
media_image4.png
Greyscale
Pyne et al. teaches the N-tosyl derivative of L-phenylalanine, compound 7. Pyne et al. defines Ts as p-CH3-C6H4SO2 (see compound below). (page 5960, second column, last paragraph; page 5961, Scheme I, compound 7):
PNG
media_image5.png
187
194
media_image5.png
Greyscale
PNG
media_image2.png
380
572
media_image2.png
Greyscale
Pyne et al. compound 7 reads on applicant’s compound of formula (I):
Z = 4-methyl substituted phenyl
L = bond
A1 =
PNG
media_image6.png
187
184
media_image6.png
Greyscale
R1 =
PNG
media_image7.png
130
90
media_image7.png
Greyscale
where R4 = Ra1 = Ra2 = H, T2 = phenyl and Y2 = OH (ORa, Ra = H)
R1 has no R2. Thus the proviso of claim 1 does not apply.
With regard to claims 15-17, compound 7 is a compound of formula (II) (see compound (II) below), Ar-S(O)2-NH-R1, where Ar is 4-methylphenyl. Claim 16 recites Ar as phenyl with X1 at the 4-position, where X1 is methyl. Claim 17 recites Ar as 4-methylphenyl.
PNG
media_image8.png
70
122
media_image8.png
Greyscale
Therefore these claims are fully met.
Double Patenting
The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the “right to exclude” granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory double patenting rejection is appropriate where the claims at issue are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., In re Berg, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); In re Goodman, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); In re Longi, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); In re Van Ornum, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); and In re Thorington, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).
A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on a nonstatutory double patenting ground provided the reference application or patent either is shown to be commonly owned with this application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement. A terminal disclaimer must be signed in compliance with 37 CFR 1.321(b).
The USPTO internet Web site contains terminal disclaimer forms which may be used. Please visit http://www.uspto.gov/forms/. The filing date of the application will determine what form should be used. A web-based eTerminal Disclaimer may be filled out completely online using web-screens. An eTerminal Disclaimer that meets all requirements is auto-processed and approved immediately upon submission. For more information about eTerminal Disclaimers, refer to http://www.uspto.gov/patents/process/file/efs/guidance/eTD-info-I.jsp.
This is a provisional obviousness-type double patenting rejection because the conflicting claims have not in fact been patented.
Claims 1, 15-17 and 31 are provisionally rejected on the ground of nonstatutory double patenting as being unpatentable over claims 45, 81 and 82 of copending Application No. 18993421 (the PGPub is used herein: US 20260265190). Although the claims at issue are not identical, they are not patentably distinct from each other because of the following:
Copending application’s claim 81 recites the following compounds:
1) N-(1-(3,4-difluorophenyl)-2-(piperazin-1-yl)ethyl)-4-(trifluoromethoxy)benzenesulfonamide (page 18); and
2) N-(1-(3,4-dichlorophenyl)-2-(dimethylamino)ethyl)-4-(3-(trifluoromethyl)phenoxy)benzenesulfonamide (page 20; claim 45, page 17).
Compound 1) reads on instant claims 1, 15-17, 23 and 26, when:
Z = Ar = 4-trifluoromethoxy substituted phenyl; L = bond; A1 = -S(=O)2-NH-R1
R1 = the first R1 group, where R2 = 3,4-difluorophenyl, R4 = Ra1 = Ra2 = H, and RA and RB combine to form a piperazine (A2 = 3,4-difluorophenyl and A3 = piperazin-1-yl of claim 23)
Proviso (a) of claim 1 is met. The phenyl in Z has a trifluoromethoxy and R2 has a fluoro.
Compound 2) reads on the instant claims, when:
Z = Ar = 4-(3-(trifluoromethyl)phenoxy) substituted phenyl;
L = bond;
A1 = -S(=O)2-NH-R1
R1 = the first R1 group, where R2 = 3,4-dichlorophenyl, R4 = Ra1 = Ra2 = H, and
RA = RB = methyl
Proviso (a) of claim 1 is met. The phenyl in Z has a C6-C10 aryloxy and R2 has a chloro.
Thus copending application’s claims 45 and 81 anticipate instant claims 1, 15-17 and 31
Copending application’s claim 82 recites a pharmaceutical composition of the compounds of claim 1 and a pharmaceutically acceptable carrier.
Thus it would be obvious to also combine compound 1) or 2) above with a pharmaceutically acceptable carrier, to use them as PP2A modulators.
Conclusion
No claim is allowed.
Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, THIS ACTION IS MADE FINAL. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).
A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the date of this final action.
Any inquiry concerning this communication or earlier communications from the examiner should be directed to Jennifer Cho Sawyer whose telephone number is (571) 270 1690. The examiner can normally be reached on Monday-Friday 9 AM - 6 PM PST.
If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Renee Claytor can be reached on (571) 272-8394. The fax phone number for the organization where this application or proceeding is assigned is 571-274-1690.
Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.
/JENNIFER C SAWYER/Examiner, Art Unit 1691
/RENEE CLAYTOR/Supervisory Patent Examiner, Art Unit 1691